New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials
A team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, studied survival outcomes of Ovarian Clear Cell Carcinoma (OCCC) patients treated with immune checkpoint blockade therapy (clinicaltrials.gov identifier: NCT03026062). The ;study showed that patients having tumors with inactivating mutations in PPP2R1A - the major scaffold subunit of protein phosphatase 2A (PP2A) - had significantly better overall survival, compared with patients who did not have this mutation in their tumors.
Inactivating mutations in PPP2R1A are known to reduce the enzymatic activity of PP2A, which is the target of LIXTE's lead compound LB-100. Tumors with mutations in PPP2R1A were found to have increased the interferon gamma response pathway, which is known to be associated with improved immune checkpoint responses.
LIXTE is currently investigating the activity of LB-100 in combination with checkpoint immunotherapy in two clinical trials. The first is enrolling patients with OCCC, led by Dr. Jazaeri at MD Anderson Cancer Center, and also is open at Northwester University. In this trial, LIXTE is collaborating with GSK to test LB-100 in combination with dostarlimab (anti PD1). In the second trial, at the Netherlands Cancer Institute, LIXTE is collaborating with Roche to test LB-100 in combination with atezolizumab (anti PDL1) in colon cancer patients.
'Not only did we identify a new biomarker for improved survival with immunotherapy in ovarian cancer, but we also confirmed the correlation of this biomarker with survival benefit in other cancer types,' said Dr. Jazaeri, who was co-senior author of the Nature article. 'Since PPP2R1A mutations are relatively uncommon, we believe the same benefits may be possible by targeting the PPP2A pathway using drugs, which we currently are evaluating in a clinical trial at MD Anderson.'
Bas van der Baan, LIXTE's Chief Scientific Officer, added, 'This work extends a body of pre-clinical evidence indicating that LB-100 is strongly synergistic with checkpoint immunotherapy in a range of cancer types. We look forward to the first results of our clinical studies in the second half of this year.'
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company's ability to obtain and maintain compliance with Nasdaq's continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company's filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information about LIXTE, Contact:
For more information about LIXTE, Contact: info@lixte.com General Phone: (631) 830-7092; Investor Phone: (888) 289-5533orPondelWilkinson Inc. Investor Relations pwinvestor@pondel.comRoger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962Erreur lors de la récupération des données
Connectez-vous pour accéder à votre portefeuille
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Geek Wire
22 minutes ago
- Geek Wire
Pacific Northwest tech pioneers team up in quantum realms and on the space frontier
At left: Microsoft's Majorana quantum chip. At right: Xplore's Xcraft satellite. (Credits: Microsoft / Xplore) BELLEVUE, Wash. — Quantum physics and outer space may seem as different as two tech frontiers can be, but the challenges facing Pacific Northwest ventures that are aiming to make their fortune on those frontiers are surprisingly similar. Amid the current turbulence on the national political scene, it's getting harder to capture the attention — and gain the support — of the federal government, which has historically been the leading funder of research and development. And that means it's more important than ever for researchers, industry leaders and local officials to join forces. 'Think of it as a triad,' said Jason Yager, executive director of the Montana Photonics and Quantum Alliance, which is one of the beneficiaries of a $41 million Tech Hub grant awarded by the federal government a year ago. 'If all of these pieces are working together, then where they meet is socio-economic growth, and then you're ready to bring in the additional funding to launch that.' Yager and other tech leaders from the northwest U.S. and western Canada compared notes today at the Hyatt Regency Bellevue during the Pacific Northwest Economic Region's annual summit. The topics covered at this week's sessions included AI and aviation — tech frontiers in which the Pacific Northwest has had a longstanding leadership role, thanks to the likes of Boeing, Microsoft and Amazon. In contrast, the frontiers of space commerce and quantum information sciences are far less settled. To be sure, there are grand aspirations. 'We like to say we're the Silicon Valley of space here in Puget Sound,' Sen. Maria Cantwell, D-Wash., said last year at the opening of Amazon's Project Kuiper satellite factory in Kirkland, Wash. And a couple of years ago, regional tech leaders said Washington state has a chance to create a 'Quantum Valley' modeled after Silicon Valley. But in both realms, other regions — ranging from California to Colorado to Chicago — are competing for attention. 'I'm tired of students getting admitted to Berkeley and University of Washington, and having them pick Berkeley,' said Charles Marcus, a UW professor who heads up a public-private consortium called the Northwest Quantum Nexus. 'I want them to pick University of Washington. I want to be better than Berkeley. That's going to take some concentration, but the rewards are big.' The quantum perspective One of the items on Marcus' to-do list is to get the Northwest Quantum Nexus' website back online. The Nexus was established back in 2019 by UW, Microsoft and the Pacific Northwest National Laboratory to bring together researchers, developers and business leaders in the field of quantum computing. While classical computers process binary bits that can only represent ones or zeroes, quantum computers work with qubits that can represent multiple values simultaneously until the results are read out. The technique — which makes use of superconducting circuits or trapped ions — can theoretically execute certain types of algorithms much faster than classical techniques can. Researchers are closing in on the creation of quantum hardware that will be able to follow through on those theoretical promises. Last week, for example, a Danish consortium announced that it would host what it called the world's most powerful quantum computer by the end of next year, with Microsoft providing the software. Marcus and his colleagues acknowledge that they don't yet know exactly what quantum computers will be capable of. 'It's kinda like you're trying to predict what computers are going to do, pre-ENIAC, pre-vacuum tube, like getting into mechanical computers,' said John Gamble, senior director of architecture at IonQ. That company is headquartered in Maryland but opened a quantum computer factory in Bothell, Wash., last year. University of Washington Professor Charles Marcus stretches out his arm to make a point during a quantum tech forum at the Pacific Northwest Economic Region's annual summit. Other panelists include Jason Yager, executive director of the Montana Photonics and Quantum Alliance, to Marcus' left; Nardo Manaloto, managing partner at Qubit Ventures; John Gamble, senior director of architecture at IonQ; and Alison Berg, chief marketing officer at Photonic Inc. (GeekWire Photo / Alan Boyle) This type of quantum uncertainty can make it difficult to catch the attention of funders and investors. But the Montana Photonics and Quantum Alliance has been meeting with success by focusing on workforce development. Yager compared the strategy to what happened during the California Gold Rush in 1848. 'There were some miners who struck it rich and became millionaires,' he said. 'There were some who made a living. There were some who lost their shirts. But there were others who did really well, and those were the ones in the supply chain. We still see Wells Fargo today. There's Levi's being worn here in the room that came out of that gold rush, that supply chain.' Similarly, the skills required for quantum development can be applied to other tech fields. In Montana, the graduates of Gallatin College's photonics and laser technology program have gone on to successful careers in communications, defense, homeland security, medical devices and information technology. Looking more broadly at the quantum landscape, Yager said he was worried that America was falling behind other countries. 'We just don't have the political will at this time to compete,' he said. 'And I hate to say that, because that's historically not been the case for the United States. But with the National Quantum Initiative that funded, to date, $2.6 billion, and China at $138 billion — it's an order of magnitude.' Marcus is also worried about future funding. 'We've all heard the reports from the National Science Foundation. They are dire. They will be brain-draining,' he said. 'I assure you that scientists will be fine. They'll just be somewhere else.' He highlighted the need to upgrade academic facilities that focus on physics and materials science. 'The buildings are underfunded, and I don't have a clue about how to solve that problem,' Marcus said. 'But I leave it to the smart people in this room to think of a solution to keep the facilities at the universities in our region A-plus, because people will vote with their feet.' Which brings us back to the Northwest Quantum Nexus' website. When Marcus took on the lead role at the Nexus, he completely reworked its mission. 'The new director of it — who is me — flattened the organization and said the door is open. Come in and join,' he said. 'If you're from a state that is arguably not in the Pacific Northwest, or is, come on in. Be with us. If you're from a company that maybe doesn't have your headquarters in the Pacific Northwest, come on in. Be with us.' In the meantime, the Northwest Quantum Nexus' domain registration lapsed, and by the time Marcus was able to renew it, the website had been wiped clean. Now the site is being redesigned with financial support from the Washington Technology Industry Association. 'We're going to be offline for about a month … and then we're going to be great,' Marcus said. The space perspective The Pacific Northwest's space industry isn't facing quite as much uncertainty as the region's quantum community. For example, more than half of the world's satellites are built at SpaceX's facility in Redmond, Wash. And that's not all. Satellite factories operated in the Seattle area by Amazon's Project Kuiper, Aerojet Rocketdyne / L3Harris, LeoStella and Xplore add to the tally. Kent, Wash.-based Blue Origin, founded by Jeff Bezos, rates as the region's biggest space company — and there are scores of other Pacific Northwest space companies including Stoke Space, Starfish Space, Gravitics, Hubble Network, Interlune, Kymeta, New Frontier Aerospace, Radian Aerospace and RBC Signals. But when it comes to getting attention from the rest of the world, the Pacific Northwest has to fight for attention. 'There are two or three locations that get all the love from the leadership — local, state level, province level and at the federal level. That is L.A.; the greater Denver area in Colorado; and Washington, D.C.,' said Jeff Thornburg, CEO of Bothell, Wash.-based Portal Space Systems. 'I see an opportunity for the Pacific Northwest region to start to create that center of influence here that doesn't really quite exist yet.' Hector Huguet, director of strategic solutions at Redmond-based Kymeta, gestures during a space industry panel at the Pacific Northwest Economic Region's annual summit. Other panelists include Kristen Smithson, vice president for production and supply chain at BlackSky, which is based in Virginia but has a substantial Seattle-area presence; Lisa Rich, co-founder and chief operating officer at Bellevue-based Xplore; and Jeff Thornburg, CEO of Bothell-based Portal Space Systems. (GeekWire Photo / Alan Boyle) It's not just a matter of bragging rights: The Pacific Northwest's space ecosystem needs a critical mass to attract the officials who decide which companies receive billions of dollars in government contracts for space services. 'It's very difficult to get the U.S. political leadership out to Seattle to see all of the things that are going on, because typically they spend their travel time in D.C., Colorado and California,' Thornburg said. Lisa Rich, co-founder and chief operating officer for Bellevue-based Xplore, said other regions seem more willing to provide direct support to space startups. 'We have friends in Colorado that have startups where they've been given free rent for a year. … Effectively, my understanding is that they could have an employee for six months and have that funded,' she said. Michael Doyle, co-founder and president of Space Northwest, noted that some of the perks that other states can offer aren't allowed under Washington state law. 'That's why we seek other ways to do it,' he said. 'But it's not easy.' Space Northwest serves as an association for the Pacific Northwest's space industry, and there are other groupings as well. In 2023, the city of Redmond provided a spotlight for its space presence, including SpaceX's satellite operation, by establishing the 'Redmond Space District.' Now Rich is trying to create a similar grouping she calls the '405 Space Data Corridor' to bring attention to Xplore and other Eastside companies that specialize in satellite data products. 'It's so impactful to just see what's happening here, and that it's not just the big companies,' Rich said. 'There's a whole ecosystem of companies that are popping up around them. There have been engineers that have worked at those large companies and have seen an opportunity that they weren't able to get through, and they said, 'You know what? I'm going to start my own business.' And so, yes, we've seen that in L.A., and I think we're seeing it more and more in the Pacific Northwest.' Doyle is hopeful that the Pacific Northwest will get its turn in the space spotlight. 'I feel like the critical mass is coming together,' he said.
Yahoo
25 minutes ago
- Yahoo
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. ( ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastatic colorectal cancer (mCRC). This randomized, controlled, multi-center Phase III clinical trial for first-line treatment of mCRC is one of the company's key initiatives to address the significant unmet clinical need worldwide with ivonescimab. Colorectal cancer remains the third most common cancer globally and the second leading cause of cancer-related deaths. In 2022, over 1.9 million new cases were reported, with approximately 904,000 deaths. Of these, about 95% of mCRC cases are classified as microsatellite stable (MSS) or proficient mismatch repair (pMMR), which traditionally show poor responses to immunotherapy and the tumors are often referred to as an "immune desert." For first-line treatment of MSS/pMMR-type mCRC, which represents up to 95% of cases, several PD-1/L1 inhibitors have been explored in multiple international studies. However, the efficacy has been limited, and as of now, no first-line immunotherapy has been approved globally for patients with pMMR/MSS-type mCRC. Chemotherapy combined with targeted therapies (such as bevacizumab, cetuximab, etc.) remains the standard first-line treatment for mCRC, though its overall efficacy is limited, with a five-year survival rate for advanced patients of less than 20%. Bevacizumab is the most well-established and clinically impactful treatment in the mCRC space. It is also one of the core indications of bevacizumab. At the 2024 European Society for Medical Oncology (ESMO) Congress, Professor Yanhong Deng from the Sixth Affiliated Hospital of Sun Yat-sen University, presented promising Phase II efficacy data of ivonescimab in combination with chemotherapy for first-line treatment of MSS/pMMR-type mCRC. The combination of ivonescimab with FOLFOXIRI demonstrated compelling anti-tumor activity in this hard to treat patient population, with an overall response rate (ORR) of 81.8% and a disease control rate (DCR) of 100%. After a median follow-up of 9 months, the median progression-free survival (mPFS) was not reached, with a 9-month PFS rate of 81.4%. Regardless of KRAS/BRAF mutation status, patients can benefit from ivonescimab combination therapy. The results published at the 2024 ESMO suggest that ivonescimab may offer a significant improvement over existing treatment options for MSS/pMMR mCRC patients. The Phase III trial AK112-312/HARMONi-GI6 can potentially further validate the clinical benefits of ivonescimab in this setting, offering a novel first-line immunotherapy treatment option for patients with advanced mCRC. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. ( "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About Akeso Akeso (HKEX: is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit and follow us on Linkedin. View original content: SOURCE Akeso, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
SpaceX delays launch of NASA TRACERS mission until Wednesday
July 22 (UPI) -- The NASA TRACERS mission is set to launch on Wednesday atop a SpaceX Falcon 9 rocket after SpaceX postponed Tuesday's launch due to "airspace concerns." SpaceX officials scrubbed Tuesday's launch at Vandenberg Space Force Base in California just 45 seconds before liftoff. The launch was canceled "due to [Federal Aviation Administration] airspace concerns that created a no-go condition for launch," SpaceX posted on social media. Wednesday's launch is scheduled for 11:13 a.m. PDT with a 57-minute launch window to send NASA's twin Tandem Reconnection and Cusp Electrodynamics Reconnaissance Satellites into orbit. The TRACERS mission aims to "help understand magnetic reconnection and its effects in Earth's atmosphere." NASA will also send three payloads, the Athena EPIC, the Polylingual Experimental Terminal and the Relativistic Electron Atmospheric Loss, with the mission. The mission's launch window opens at 11:13 a.m. PDT on Wednesday with a 57-minute window from the Vandenberg Space Force Base's Space Launch Complex 4 East. About eight minutes after liftoff, Falcon 9's first stage will land on SpaceX's Landing Zone 4 at Vandenberg Space Force Base, according to SpaceX. "There is the possibility that residents of Santa Barbara, San Luis Obispo, and Ventura counties may hear one or more sonic booms during the landing, but what residents experience will depend on weather and other conditions," SpaceX officials said.
